In endometrial cancer, treatment of AN3CA cells with varying concentrations of BF175 for 24 h resulted in a significant, dose-dependent reduction in SREBP2 expression, demonstrating antitumor activity (Wang et al., 2021). Here, SREBF2 is linked to endometrial cancer.